Abstract | AIM: METHODS: 300 patients, detected on active search in Agra district, who had single lesion leprosy but no nerve thickening, were randomly allocated (using random number table) to two treatment groups, 151 to ROM and 149 to C-ROM. All th patients were given single dose of ROM or C-ROM and followed up every 6 months for disease status, cure rate, reaction and relapse. Survival analysis was used to compare relapse rate. RESULTS: The cure rate at 2 years was 93.1% in ROM and 91.4% in C-ROM group. By this time three relapses had occurred in the ROM group while two patients were found to have relapsed in the C-ROM group. Thus, there was no statistical difference in relapse rates (2.1% vs. 1.41%, P = 0.287) in the two groups. Long term observations over 3-5 years revealed nine relapses (five in ROM, four in C-ROM) giving relapse rate of 1.05/100 Person years in ROM and 0.90/100 person years in C-ROM group--again no significant difference was observed (P = 0.87). CONCLUSION: The study shows that addition of clarithromycin to ROM does not significantly improve the efficacy as measured in terms of cure rates and relapse rates in single skin lesion leprosy patients.
|
Authors | Anita Girdhar, Anil Kumar, Bhawneswar Kumar Girdhar |
Journal | Leprosy review
(Lepr Rev)
Vol. 82
Issue 1
Pg. 46-54
(Mar 2011)
ISSN: 0305-7518 [Print] England |
PMID | 21644471
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Ofloxacin
- Minocycline
- Clarithromycin
- Rifampin
|
Topics |
- Adolescent
- Adult
- Child
- Child, Preschool
- Clarithromycin
(therapeutic use)
- Female
- Humans
- India
(epidemiology)
- Leprosy, Paucibacillary
(drug therapy, epidemiology)
- Male
- Middle Aged
- Minocycline
(therapeutic use)
- Ofloxacin
(therapeutic use)
- Recurrence
- Rifampin
(therapeutic use)
- Survival Analysis
- Treatment Outcome
|